Table 3 BARS responder classification
Mepolizumab, n = 129 | Benralizumab, n = 83 | Dupilumab, n = 68 | Inter-group comparison | |
|---|---|---|---|---|
BARS Score at V1 (6 months) | ||||
Good Response, n (%) | 65 (50) | 37 (45) | 33 (49) | 0.460 |
Intermediate Response, n (%) | 45 (35) | 33 (40) | 25 (37) | |
Insufficient Response, n (%) | 6 (5) | 9 (11) | 7 (10) | |
Data incomplete, n (%) | 13 (10) | 4 (5) | 3 (4) | |
BARS Score at V2 (12 months) | ||||
Good Response, n (%) | 64 (50) | 44 (53) | 35 (51) | 0.928 |
Intermediate Response, n (%) | 57 (44) | 33 (40) | 27 (40) | |
Insufficient Response, n (%) | 6 (5) | 5 (6) | 6 (9) | |
Data incomplete, n (%) | 2 (1) | 1 (1) | – | |